Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terns Pharmaceuticals ( (TERN) ) has shared an announcement.
On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 CARDINAL trial of TERN-701 in patients with relapsed/refractory chronic myeloid leukemia has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting on December 8, 2025. The trial showed a 75% major molecular response rate by 24 weeks, with TERN-701 exhibiting a strong safety profile and no dose-limiting toxicities. These results suggest TERN-701’s potential as a leading therapy for chronic myeloid leukemia, offering significant opportunities across all treatment lines.
The most recent analyst rating on (TERN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Terns Pharmaceuticals stock, see the TERN Stock Forecast page.
Spark’s Take on TERN Stock
According to Spark, TipRanks’ AI Analyst, TERN is a Neutral.
Terns Pharmaceuticals’ overall score reflects significant financial challenges due to lack of revenue and ongoing losses. Despite strong cash reserves and low debt, the company faces high risk due to persistent cash burn. The stock’s technical indicators suggest a bearish trend, and its negative valuation factors further hinder attractiveness. However, the new CFO appointment could enhance strategic financial management, offering a glimmer of potential improvement.
To see Spark’s full report on TERN stock, click here.
More about Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company focused on developing high-impact medicines by reimagining known biology. Their lead program, TERN-701, is an oral, allosteric BCR-ABL inhibitor designed to improve efficacy, safety, and convenience for chronic myeloid leukemia treatments.
Average Trading Volume: 1,321,301
Technical Sentiment Signal: Buy
Current Market Cap: $722.8M
For a thorough assessment of TERN stock, go to TipRanks’ Stock Analysis page.